SCHEMBL50379

SCHEMBL50379

CS(=O)(=O)NCCN1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.52
PRMT6 Q96LA8 1/20 0.52
PRMT8 Q9NR22 1/20 0.52
SIGMAR1 Q99720 7/20 0.49
KDM1A O60341 1/20 0.43
MBTD1 Q05BQ5 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8604390 0.98 SIGMAR1 (0.50) CARM1PRMT6PRMT8SIGMAR1KDM1A
SCHEMBL21610873 0.88 L3MBTL1 (0.55) CARM1PRMT6PRMT8SIGMAR1MBTD1
SCHEMBL4710735 0.86 L3MBTL1 (0.50) CARM1PRMT6PRMT8SIGMAR1MBTD1
SCHEMBL23775348 0.82 ALOX15 (0.50) SIGMAR1KDM1AALOX15MEN1KMT2A
SCHEMBL1985719 0.82 HSD17B10 (0.46) SIGMAR1KDM1AL3MBTL1KDM4EGAA
SCHEMBL14500308 0.82 ALDH1A1 (0.43) KDM1AKDM4EMAPTSMN1; SMN2TSHR
SCHEMBL1861919 0.82 ALDH1A1 (0.52) L3MBTL1SMN1; SMN2TSHRMAPK1
SCHEMBL7518279 0.80 HSD17B10 (0.44) SIGMAR1KDM1AL3MBTL1KDM4EGAA
Hydrochloric Acid SCHEMBL27700557 0.80 HSD17B10 (0.44) SIGMAR1KDM1AL3MBTL1KDM4EGAA
Hydrochloric Acid SCHEMBL1547324 0.80 HSD17B10 (0.44) SIGMAR1KDM1AL3MBTL1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-7156912-B2 Colored composition TOYO INK MFG. CO., LTD. (JP) 2007-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B CARM1 1560/4885PRMT6 785/4885PRMT8 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.